EDITOR
	Neil Love, MD Medical Oncologist Editor, Breast Cancer Update for Nurses Research To Practice Miami, Florida
FACULTY AFFILIATIONS
	Robert W Carlson, MD Professor of Medicine Division of Oncology and Stanford Medical Informatics Stanford University Medical Center Stanford, California		Clifford Hudis, MD Chief, Breast Cancer Medicine Service Solid Tumor Division Memorial Sloan-Kettering Cancer Center New York, New York
	Anne P O’Connor, RN, MSN, AOCN Clinical Nurse Coordinator — Oncology Lombardi Comprehensive Cancer Center Washington, DC

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest, either current or within the past 12 months, for themselves (or their spouses/partners) that have been resolved through a peer review process: John Brebner, Richard Kaderman, PhD, Neil Love, MD, Paula Mateo, RN, BA, Donna Neil, RNC, Douglas Paley, Margaret Peng, Fredrica Preston, RNC, NP, AOCN, Lilliam Sklaver Poltorack, PharmD, Ginelle Suarez, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Aviva Asnis-Alibozek, PA-C, MPAS — salary: AstraZeneca Pharmaceuticals LP; shareholder of AstraZeneca Pharmaceuticals LP; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech BioOncology. Research To Practice receives education grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, GPC Biotech, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Carlson — Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Taiho Pharmaceutical Co Ltd; Consulting Fees: AstraZeneca Pharmaceuticals LP, Genomic Health Inc, Pfizer Inc. Dr Hudis — Consulting Fees: AstraZeneca Pharmaceuticals LP, Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Kosan Biosciences, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis; Contracted Research: Breast Cancer Research Foundation, Kosan Biosciences, National Cancer Institute, National Institutes of Health; Shareholder: Genomic Health Inc. Ms O’Connor — Shareholder: Abraxis BioScience.

---

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Table of Contents

Top of Page